Insmed reported $-115292000 in Pre-Tax Profit for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Pre Tax Profit Change
Acelrx Pharmaceuticals ACRX:US $ -8.38M 1.47M
Alexion Pharmaceuticals ALXN:US $ 940.1M 164.6M
Alimera Sciences ALIM:US $ -4.35M 10.06M
Arena Pharmaceuticals ARNA:US $ -126.31M 19.78M
Cytokinetics CYTK:US $ -76.09M 14.53M
Flexion Therapeutics FLXN:US $ -30312000 8.1M
Insmed INSM:US $ -115292000 1.41M
Mirati Therapeutics MRTX:US $ -76.76M 89.68M
Novartis NVS:US $ 4544M 120M
Regeneron Pharmaceuticals REGN:US $ 1822.2M 2076.1M
Sarepta Therapeutics SRPT:US $ -47.91M 33.85M
Ultragenyx Pharmaceutical RARE:US $ -72.82M 49.15M